Related references
Note: Only part of the references are listed.Cancer Statistics, 2009
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2009)
Impact of the Duration of Adjuvant Hormonal Therapy in Patients With Locally Advanced Prostate Cancer Treated With Radiotherapy: A Secondary Analysis of RTOG 85-31
Luis Souhami et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Duration of Androgen Suppression in the Treatment of Prostate Cancer
Michel Bolla et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Ten-year follow-up of radiation therapy oncology group protocol 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer
Eric M. Horwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Osteoporosis in men
Peter R. Ebeling
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Androgren-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know?
Celestia S. Higano
NATURE CLINICAL PRACTICE UROLOGY (2008)
Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy
Christopher W. Ryan et al.
UROLOGY (2007)
Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer
M. Dror Michaelson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Androgen deprivation in veterans with prostate cancer: Implications for skeletal health
Andrew Wilcox et al.
ANNALS OF PHARMACOTHERAPY (2006)
Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer
SL Greenspan et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Assessment of fracture risk
JA Kanis et al.
OSTEOPOROSIS INTERNATIONAL (2005)
Health care utilization and expenditures in the United States: a study of osteoporosis-related fractures
LS Orsini et al.
OSTEOPOROSIS INTERNATIONAL (2005)
Physician practices of bone density testing and drug prescribing to prevent or treat osteoporosis during androgen deprivation therapy
T Tanvetyanon
CANCER (2005)
Risk of fracture after androgen deprivation for prostate cancer
VB Shahinian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy - Recommendations for diagnosis and therapies
TH Diamond et al.
CANCER (2004)
Bone loss and the evolving role of bisphosphonate therapy in prostate cancer
CS Higano
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2003)
Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer
MR Smith et al.
JOURNAL OF UROLOGY (2003)
Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community:: randomised double blind controlled trial
DP Trivedi et al.
BMJ-BRITISH MEDICAL JOURNAL (2003)
A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma
F Saad et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2002)
Hormone therapy for locally advanced prostate cancer
JE Fowler et al.
JOURNAL OF UROLOGY (2002)
Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.
MR Smith et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
